Galectin Therapeutics Inc (GALT)

1.78
0.00 (0.00)
NASDAQ : Health Care
Prev Close 1.78
Open 1.80
Day Low/High 1.76 / 1.88
52 Wk Low/High 1.08 / 3.33
Volume 51.13K
Avg Volume 157.90K
Exchange NASDAQ
Shares Outstanding 35.05M
Market Cap 64.50M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Patent For Enhancing Immunotherapy In Cancer Treatment Granted To Galectin Therapeutics

Patent For Enhancing Immunotherapy In Cancer Treatment Granted To Galectin Therapeutics

Patent supports the Combination Immunotherapy trial utilizing GR-MD-02, now completed enrollment of second ascending dose cohort

Patent For Reducing Inflammatory Response Granted To Galectin Therapeutics

The patent extends the Company's coverage to areas of future clinical investigation in diseases associated with elevations in iNOS

Galectin Therapeutics Announces Important Milestones Towards Completion Of NASH CX Trial

Independent data safety monitoring board determines no safety issues in patients with NASH cirrhosis enrolled in NASH-CX trial

Galectin Therapeutics And Exalenz To Present Late-Breaking Abstract At The International Liver Congress™ 2017

13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis

GALT Crosses Above Average Analyst Target

In recent trading, shares of Galectin Therapeutics Inc have crossed above the average analyst 12-month target price of $2.08, changing hands for $2.30/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Interesting GALT Put Options For May 19th

Investors in Galectin Therapeutics Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALT options chain for the new May 19th contracts and identified the following put contract of particular interest.

Combination Immunotherapy With Galectin-3 Inhibitor GR-MD-02 Enhances Effects In Pre-clinical Models And Early Results Of Phase 1 Clinical Trials

First-in-human data presented at GTCBio 9th Immunotherapeutics & Immunomonitoring Conference

Galectin Therapeutics Announces $4 Million In New Equity Financings

Galectin Therapeutics Announces $4 Million In New Equity Financings

Common and Preferred private placements completed at above market prices

Galectin Therapeutics Announces Positive New Psoriasis And Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships For Therapy Of Severe Skin Diseases

Galectin Therapeutics Announces Positive New Psoriasis And Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships For Therapy Of Severe Skin Diseases

Meaningful activity of GR-MD-02 in treating psoriasis and preliminary data in treating atopic dermatitis suggests promise in treatment of serious skin disease

Galectin Therapeutics To Present Clinical Data On Selective Non-Invasive Tests For The Development Of Novel Therapies For Nonalcoholic Steatohepatitis

Galectin Therapeutics To Present Clinical Data On Selective Non-Invasive Tests For The Development Of Novel Therapies For Nonalcoholic Steatohepatitis

Research to be presented at The Liver Meeting® 2016 demonstrates correlation of FibroScan and MRE as non-invasive tests to assess the progression of liver fibrosis and cirrhosis

Galectin Therapeutics (GALT) Stock Drops on Drug Failure, Downgraded

Galectin Therapeutics (GALT) Stock Drops on Drug Failure, Downgraded

H.C. Wainwright reduced Galectin Thereapeutics' (GALT) stock rating to 'neutral' after the company's fatty liver disease drug failed in a phase II clinical trial.

Galectin Therapeutics (GALT) Stock Declines on Drug Failure, Rating Cut

Galectin Therapeutics (GALT) Stock Declines on Drug Failure, Rating Cut

Galectin Therapeutics' (GALT) stock rating was cut two notches to 'sell' at Roth Capital on Wednesday after the company's drug for fatty liver disease failed a clinical trial.